Volume 57, Issue 2 pp. 202-208
Report

Bullous pemphigoid complicated by cytomegalovirus disease as a manifestation of immune reconstitution inflammatory syndrome: retrospective analyses of our institutional cases and literature review

Yoko M. Narita MD

Corresponding Author

Yoko M. Narita MD

Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan

Correspondence

Yoko M. Narita, md

Department of Dermatology, Kyorin University School of Medicine

6-20-2 Shinkawa Mitaka

Tokyo, 181-8611

Japan

E-mail: [email protected]

Search for more papers by this author
Chiho Horie MD

Chiho Horie MD

Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan

Search for more papers by this author
Kazuhisa Hirahara MD

Kazuhisa Hirahara MD

Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan

Search for more papers by this author
Yoko Kano MD

Yoko Kano MD

Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan

Search for more papers by this author
Tetsuo Shiohara MD

Tetsuo Shiohara MD

Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan

Search for more papers by this author
Yoshiko Mizukawa MD

Yoshiko Mizukawa MD

Department of Dermatology, Kyorin University School of Medicine, Tokyo, Japan

Search for more papers by this author
First published: 02 December 2017
Citations: 7
Funding: This article has no funding source.
Conflict of interest: The authors have no conflict of interest to declare.

Abstract

Background

Cytomegalovirus (CMV) disease induced by reactivation of latent CMV is a fatal viral infection that may develop in a setting of therapy with immunosuppressive agents. There is a clear need to clarify any clinical features and markers of CMV disease.

Objective

We investigated which clinical markers usually available in a clinical setting can predict CMV disease occurring in bullous pemphigoid (BP) patients receiving corticosteroids.

Method

We described a BP patient with CMV disease complicated by gastrointestinal hemorrhage and liver dysfunction. Prompted by this patient, we retrospectively analyzed clinical features and laboratory findings in our institutional four BP patients and previously reported nine BP patients with CMV disease. We also compared these patients with our institutional 42 BP patients not complicated by CMV disease.

Results

High levels of anti-BP180 antibody titers associated with resistance to corticosteroids are a risk factor for the development of CMV disease. A reduction in platelet (PLT) and white blood cell (WBC) counts and an increase in alanine aminotransferase (ALT) levels 3–4 weeks after the initiation of corticosteroids are useful predictive markers for the onset of CMV disease.

Conclusions

Frequent WBC, PLT, and ALT measurements may identify BP patients at a risk of subsequently developing CMV disease. Careful monitoring of CMV disease in BP refractory to systemic corticosteroids may reduce the risk of fatal outcomes.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.